Preferred Partnership Program
The BostonGene Preferred Partnership Program is a collaboration between community, academic, and industry physicians and scientists from leading centers across the world. The goal of our program is bringing scientific discoveries to clinics using a comprehensive BostonGene analytical solution integrating molecular data generated by a variety of techniques, including NGS, imaging, and flow cytometry. Members of our Preferred Partnership Program enjoy BostonGene support at each step of translational research from hypothesis generation to implementation in clinics as a Standard of Care (SOC). We foster joint discovery in areas of tumor genetics, tumor microenvironment, systemic immune status and others, ultimately advancing personalized medicine for cancer patients.
BostonGene provides tailored support to Partners through discovery, development, validation, clinical trials and clinical integration. Our Partners receive access to BostonGene-integrated databases, bioinformatic support from the BostonGene team of experts, and access to wet lab data generation either in the BostonGene state of the art laboratory or via a partnership with in-house facilities. Members of our partnership participate in joint discovery, clinical validation, and even commercialization. In addition to individual member support, BostonGene’s Preferred Partnership Program fosters networking among members through the formation of disease specific expert groups and Advisory Boards.
Why join the BostonGene Partnership Program?
- Best-in-class therapy selection tools
- Multi-institution projects and alliances
- On-site NGS pipeline development “BostonGene in a Box”
- Integrated data generation and analysis pipeline
- EMR integration
- Personalization of clinical trial screening tool
- Co-branded clinical report generation
- On-demand Molecular Tumor Boards
- Joint discovery with shared commercialization
- Grant application support
- Publication support
- Care delivery modeling
Services & Supports
Large BostonGene databases include information about molecular biomarkers, treatment responses, disease prognosis, drug efficacy, adverse effects, investigational treatments, approved drugs and clinical trials. BostonGene databases are updated daily to provide the most current data available from scientific research. Through the use of BostonGene databases, our partners gain the ability to not only discover, but also cross-validate and refine novel and existing biomarkers. You are welcome to explore the online tools exemplifying our approach for a list of cancer types.
Analysis of terabits of data per patient will not be effective without expert assistance from the BostonGene team of bioinformaticians, computer scientists, immunologists, and biologists. Members of our partnership receive support of the project designated team of experts assigned for each individual project.
Wet Lab Support and Data Generation
BostonGene state-of-the-art molecular testing laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) and accredited by the College of American Pathologists (CAP) as qualified to perform high complexity clinical laboratory testing. As our Partner, you will obtain access to a variety of wet lab techniques established and optimized at our laboratory. Our technologies include WES, RNAseq, TCR/BCRseq, MxIF, Flow cytometry, scRNAseq, and others. In addition to streamlined analysis of your samples from data generation to the integrated report, we provide an opportunity to establish an on-premises NGS process providing protocols optimized for effective integration with BostonGene analytics.